Exact Mass: 394.183888
Exact Mass Matches: 394.183888
Found 167 metabolites which its exact mass value is equals to given mass value 394.183888,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Brucine
C23H26N2O4 (394.18924760000004)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents D002491 - Central Nervous System Agents > D000700 - Analgesics D007155 - Immunologic Factors CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2329 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.545 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.540 ORIGINAL_ACQUISITION_NO 5860; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; ORIGINAL_PRECURSOR_SCAN_NO 5859 CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5850; ORIGINAL_PRECURSOR_SCAN_NO 5847 CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5870; ORIGINAL_PRECURSOR_SCAN_NO 5868 CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5860; ORIGINAL_PRECURSOR_SCAN_NO 5859 CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5841; ORIGINAL_PRECURSOR_SCAN_NO 5839 CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5876; ORIGINAL_PRECURSOR_SCAN_NO 5873 CONFIDENCE standard compound; INTERNAL_ID 971; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5855; ORIGINAL_PRECURSOR_SCAN_NO 5853 [Raw Data] CBA35_Brucine_pos_40eV_1-3_01_1629.txt [Raw Data] CBA35_Brucine_pos_10eV_1-3_01_1618.txt [Raw Data] CBA35_Brucine_pos_30eV_1-3_01_1628.txt [Raw Data] CBA35_Brucine_pos_20eV_1-3_01_1627.txt [Raw Data] CBA35_Brucine_pos_50eV_1-3_01_1630.txt
Triamcinolone
CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3715; ORIGINAL_PRECURSOR_SCAN_NO 3712 H - Systemic hormonal preparations, excl. sex hormones and insulins > H02 - Corticosteroids for systemic use > H02A - Corticosteroids for systemic use, plain > H02AB - Glucocorticoids D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07X - Corticosteroids, other combinations > D07XB - Corticosteroids, moderately potent, other combinations D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AB - Corticosteroids, moderately potent (group ii) A - Alimentary tract and metabolism > A01 - Stomatological preparations > A01A - Stomatological preparations > A01AC - Corticosteroids for local oral treatment R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BA - Glucocorticoids C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AA - Corticosteroids R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AD - Corticosteroids D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BA - Corticosteroids, plain C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D000893 - Anti-Inflammatory Agents CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3708; ORIGINAL_PRECURSOR_SCAN_NO 3707 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3717; ORIGINAL_PRECURSOR_SCAN_NO 3716 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3711; ORIGINAL_PRECURSOR_SCAN_NO 3706 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3783; ORIGINAL_PRECURSOR_SCAN_NO 3781 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3714; ORIGINAL_PRECURSOR_SCAN_NO 3712 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7651; ORIGINAL_PRECURSOR_SCAN_NO 7649 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7679; ORIGINAL_PRECURSOR_SCAN_NO 7677 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7697; ORIGINAL_PRECURSOR_SCAN_NO 7693 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7704; ORIGINAL_PRECURSOR_SCAN_NO 7701 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7689; ORIGINAL_PRECURSOR_SCAN_NO 7684 CONFIDENCE standard compound; INTERNAL_ID 239; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7706; ORIGINAL_PRECURSOR_SCAN_NO 7702 CONFIDENCE standard compound; INTERNAL_ID 2400 CONFIDENCE standard compound; INTERNAL_ID 8735 Triamcinolone is a long-acting glucocorticoid, a corticosteroid receptor (corticosteroid hormone receptor) agonist, and has anti-inflammatory effects.
Triamcinolone
Triamcinolone is a C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections. It has a role as an anti-allergic agent and an anti-inflammatory drug. It is a fluorinated steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a 21-hydroxy steroid, a 3-oxo-Delta(4) steroid, a glucocorticoid, a 17alpha-hydroxy steroid, a 16alpha-hydroxy steroid, a C21-steroid hormone, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It derives from a hydride of a pregnane. Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate. Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis. Triamcinolone is a Corticosteroid. The mechanism of action of triamcinolone is as a Corticosteroid Hormone Receptor Agonist. Triamcinolone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B. A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739) See also: Triamcinolone Acetonide (active moiety of); Triamcinolone Diacetate (is active moiety of). Triamcinolone is only found in individuals that have used or taken this drug. It is a glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. H - Systemic hormonal preparations, excl. sex hormones and insulins > H02 - Corticosteroids for systemic use > H02A - Corticosteroids for systemic use, plain > H02AB - Glucocorticoids D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07X - Corticosteroids, other combinations > D07XB - Corticosteroids, moderately potent, other combinations D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AB - Corticosteroids, moderately potent (group ii) A - Alimentary tract and metabolism > A01 - Stomatological preparations > A01A - Stomatological preparations > A01AC - Corticosteroids for local oral treatment R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BA - Glucocorticoids C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AA - Corticosteroids R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AD - Corticosteroids D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BA - Corticosteroids, plain C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D000893 - Anti-Inflammatory Agents Triamcinolone is a long-acting glucocorticoid, a corticosteroid receptor (corticosteroid hormone receptor) agonist, and has anti-inflammatory effects.
cis-3-Hexenyl b-primeveroside
cis-3-Hexenyl b-primeveroside is found in tea. cis-3-Hexenyl b-primeveroside is a constituent of Camellia sinensis
1,3,8-Trihydroxy-4-methyl-2,7-diprenylxanthone
1,3,8-Trihydroxy-4-methyl-2,7-diprenylxanthone is found in fruits. 1,3,8-Trihydroxy-4-methyl-2,7-diprenylxanthone is a constituent of the fruit hulls of Garcinia mangostana (mangosteen). Constituent of the fruit hulls of Garcinia mangostana (mangosteen). 1,3,8-Trihydroxy-4-methyl-2,7-diprenylxanthone is found in fruits.
16-DHPS
C21H30O5S (394.18138500000003)
Brucine
C23H26N2O4 (394.18924760000004)
Akuammiline
C23H26N2O4 (394.18924760000004)
Akuammiline is a monoterpenoid indole alkaloid.
Brucin
C23H26N2O4 (394.18924760000004)
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents D002491 - Central Nervous System Agents > D000700 - Analgesics D007155 - Immunologic Factors
2,3-dihydro-7-hydroxy-2R*,3R*-dimethyl-2-[4-methyl-5-(4-methyl-2-furyl)-3(E)-pentenyl]-furo[3,2-c]coumarin
(E)-2-Hexenyl-??-L-arabinopyranosyl-(1鈥樏傗垎2)-??-D-glucopyranoside
2,3-dihydro-7-hydroxy-2S*,3R*-dimethyl-2-[4-methyl-5-(4-methyl-2-furyl)-3(E),7-pentenyl]-furo[2,3-b]chromone
Z-hex-3-en-1-ol O-alpha-L-arabinopyransyl (1-2)-beta-D-glucopyranoside
isobrucine
C23H26N2O4 (394.18924760000004)
A monoterpenoid indole alkaloid with formula C23H26N2O4, originally isolated from the seeds of Strychnos nux-vomica.
1,3-dihydroxy-6-methoxy-2,4-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one|1,3-dihydroxy-6-methoxy-2,4-bis(3-methylbut-2-enyl)-9H-xanthen-9-one
2,3-dihydro-7-hydroxy-2S*,3R*-dimethyl-3-[4-methyl-5-(4-methyl-2-furyl)-3(E)-pentenyl]-furo[3,2-c]coumarin
(16S)-17-Acetoxy-sarpagan-16-carbonsaeure-methylester|(16S)-17-acetoxy-sarpagane-16-carboxylic acid methyl ester|Acetylakuammidin|Monoacetylrhazin|O-Acetyl-rhazin|Polyneuridinacetat
C23H26N2O4 (394.18924760000004)
(E)-2-hexenyl alpha-L-arabinopyranosyl-(1->6)-beta-D-glucopyranoside
(-)-2beta-(3-methyl-1-oxobut-2-enyl)-2-deoxybruceol
11-Methoxyicajine|3-methoxy-19-methyl-16,19-seco-strychnidine-10,16-dione|3-Methoxy-icajin|3-methoxy-icajine|3-methoxyicajine|N-methyl-sec-pseudo-alpha-colubrine
C23H26N2O4 (394.18924760000004)
N, N-p-Cinnamoyl, caffeoylcadaverine
C23H26N2O4 (394.18924760000004)
Brucine - CASMI2016 Category 1 - Challenge 9
C23H26N2O4 (394.18924760000004)
C17H30O10_(3Z)-3-Hexen-1-yl 6-O-alpha-L-arabinopyranosyl-beta-D-glucopyranoside
C23H26N2O4_2,3-Dimethoxystrychnidin-10-one
C23H26N2O4 (394.18924760000004)
Ala Ala Ala Tyr
Ala Ala Phe Ser
Ala Ala Ser Phe
Ala Ala Tyr Ala
Ala Phe Ala Ser
Ala Phe Gly Thr
Ala Phe Ser Ala
Ala Phe Thr Gly
Ala Gly Phe Thr
Ala Gly Thr Phe
Ala Ser Ala Phe
Ala Ser Phe Ala
Ala Thr Phe Gly
Ala Thr Gly Phe
Ala Tyr Ala Ala
Phe Ala Ala Ser
Phe Ala Gly Thr
Phe Ala Ser Ala
Phe Ala Thr Gly
Phe Gly Ala Thr
Phe Gly Thr Ala
Phe Ser Ala Ala
Phe Thr Ala Gly
Phe Thr Gly Ala
Gly Ala Phe Thr
Gly Ala Thr Phe
Gly Phe Ala Thr
Gly Phe Thr Ala
Gly Gly Val Tyr
Gly Gly Tyr Val
Gly Thr Ala Phe
Gly Thr Phe Ala
Gly Val Gly Tyr
Gly Val Tyr Gly
Gly Tyr Gly Val
Gly Tyr Val Gly
Ser Ala Ala Phe
Ser Ala Phe Ala
Ser Phe Ala Ala
Thr Ala Phe Gly
Thr Ala Gly Phe
Thr Phe Ala Gly
Thr Phe Gly Ala
Thr Gly Ala Phe
Thr Gly Phe Ala
Val Gly Gly Tyr
Val Gly Tyr Gly
Val Tyr Gly Gly
Tyr Ala Ala Ala
Tyr Gly Gly Val
Tyr Gly Val Gly
Tyr Val Gly Gly
cis-3-Hexenyl b-primeveroside
1,3,8-Trihydroxy-4-methyl-2,7-diprenylxanthone
A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1,3 and 8, prenyl groups at positions 2 and 7, and a methyl group at position 4.
Urea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclopentyl-N-[4-(methylthio)phenyl]- (9CI)
C22H26N4OS (394.18272260000003)
1,2-Bis(4-methylphenyl)-1,2-diphenyl-1,2-ethanediol
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclopentyl-N-(4-methoxyphenyl)- (9CI)
C22H26N4OS (394.18272260000003)
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclopentyl-N-(3-methoxyphenyl)- (9CI)
C22H26N4OS (394.18272260000003)
4-[(Z)-1-hydroxy-3-(3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-3-oxoprop-1-enyl]benzoic acid
(2-{4-[BIS(4-FLUOROPHENYL)METHYL]PIPERAZIN-1-YL}PHENYL)METHANOL
(4-{4-[BIS(4-FLUOROPHENYL)METHYL]PIPERAZIN-1-YL}PHENYL)METHANOL
Rimacalib
C22H23FN4O2 (394.18049499999995)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
N-Allyl-5-amidinoaminooxy-propyloxy-3-chloro-N-cyclopentylbenzamide
(2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
Volon
H - Systemic hormonal preparations, excl. sex hormones and insulins > H02 - Corticosteroids for systemic use > H02A - Corticosteroids for systemic use, plain > H02AB - Glucocorticoids D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07X - Corticosteroids, other combinations > D07XB - Corticosteroids, moderately potent, other combinations D - Dermatologicals > D07 - Corticosteroids, dermatological preparations > D07A - Corticosteroids, plain > D07AB - Corticosteroids, moderately potent (group ii) A - Alimentary tract and metabolism > A01 - Stomatological preparations > A01A - Stomatological preparations > A01AC - Corticosteroids for local oral treatment R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03B - Other drugs for obstructive airway diseases, inhalants > R03BA - Glucocorticoids C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AA - Corticosteroids R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AD - Corticosteroids D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids S - Sensory organs > S01 - Ophthalmologicals > S01B - Antiinflammatory agents > S01BA - Corticosteroids, plain C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D000893 - Anti-Inflammatory Agents Triamcinolone is a long-acting glucocorticoid, a corticosteroid receptor (corticosteroid hormone receptor) agonist, and has anti-inflammatory effects.
(4aR,5aS,8aR,15bR)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one
C23H26N2O4 (394.18924760000004)
(17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl) hydrogen sulfate
C21H30O5S (394.18138500000003)
3-hydroxy-5-nitro-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine
C20H22N6O3 (394.17533019999996)
2-[Oxo-[2-[oxo-(2-phenylethylamino)methyl]anilino]methyl]-1-cyclohexanecarboxylic acid
C23H26N2O4 (394.18924760000004)
2-[[1-[[3-(2-Hydroxyethoxy)phenyl]methyl]-4-piperidinyl]methyl]isoindole-1,3-dione
C23H26N2O4 (394.18924760000004)
(2R)-2-[(4S,5S)-8-(1-cyclopentenyl)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H30N2O4S (394.19261800000004)
(2S)-2-[(4R,5R)-8-(1-cyclopentenyl)-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
C20H30N2O4S (394.19261800000004)